300 results on '"Rejto, Paul A."'
Search Results
2. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
3. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy
4. Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer
5. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
6. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer
7. Abstract 4543: Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction
8. Supplementary Table 4 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
9. Data from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
10. Supplementary Figure 1 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
11. Data from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
12. Supplementary Table 2 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
13. Supplementary Table 2 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
14. Supplementary Figure 2 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
15. Supplementary Information from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
16. Supplementary Figure Legend from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
17. Supplementary Figure 3 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
18. Supplementary Figure Legends 1-3, Table Legends 1-4 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
19. Supplementary Material: DLDA Classifier IGF Signature from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
20. Supplementary Material: DLDA classifiers IGF Pathway Score from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
21. Supplementary Table 4 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
22. Supplementary Figure 1 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
23. Supplementary Table 3 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
24. Supplementary Table 1 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
25. Supplementary Table 3 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
26. Supplementary Figures 1-13 from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor
27. Supplemental Materials and Methods from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor
28. Supplementary Methods from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
29. Supplementary Figures 1 - 5 from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
30. Simulating Disorder-Order Transitions in Molecular Recognition of Unstructured Proteins: Where Folding Meets Binding
31. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
32. Abstract A008: PanCAN SPARK: A cloud-based health data integration platform for pancreatic cancer data
33. Unraveling Principles of Lead Discovery: From Unfrustrated Energy Landscapes to Novel Molecular Anchors
34. A Mean Field Model of Ligand-Protein Interactions: Implications for the Structural Assessment of Human Immunodeficiency Virus Type 1 Protease Complexes and Receptor-Specific Binding
35. Additional file 6 of Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
36. Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib
37. Fully automated and rapid flexible docking of inhibitors covalently bound to serine proteases
38. New trends in computational structure prediction of ligand-protein complexes for receptor-based drug design
39. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer
40. Genomic Landscape of Copy Number Aberrations Enables the Identification of Oncogenic Drivers in Hepatocellular Carcinoma
41. MOESM2 of Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
42. Structure-Based and Property-Compliant Library Design of 11β-HSD1 Adamantyl Amide Inhibitors
43. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
44. Deciphering common failures in molecular docking of ligand-protein complexes
45. Examining ligand-protein interactions with binding-energy landscapes
46. Easy Does It: Reducing Complexity in Ligand-Protein Docking
47. Detecting somatic mutations with high accuracy in plasma cell-free DNA with TNER2
48. Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis
49. Monte Carlo simulations of HIV-1 protease binding dynamics and thermodynamics with ensembles of protein conformations: Incorporating protein flexibility in deciphering mechanisms of molecular recognition
50. Reduced Dimensionality in Ligand—Protein Structure Prediction: Covalent Inhibitors of Serine Proteases and Design of Site-Directed Combinatorial Libraries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.